GlassScriptPhysician profile
Emad D Nukta
NPI 1922051937
$12,935.62
in general payments reported to CMS, 2019-2025
46 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 76% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,673 · 2020: $188 · 2021: $875 · 2022: $1,786 · 2023: $1,415 · 2024: $1,888 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,958 · Travel and Lodging: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,958.02 |
| Travel and Lodging | $1,455.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,012.88 | 2019-2025 | Mitraclip, Optis, Diamondback Coronary |
| Boston Scientific Corporation | $1,929.60 | 2019-2025 | General - Therapies, Avvigo Guidance System, Eluvia |
| Abiomed | $1,337.02 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $1,054.17 | 2019-2025 | |
| Shockwave Medical, INC | $797.75 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $598.00 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $464.49 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $406.06 | 2019-2025 | |
| Celonova Biosciences, INC. | $282.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.31 | 2019-2025 | Jardiance |
| Medtronic, INC. | $248.22 | 2021-2024 | Onyx Frontier |
| E.R. Squibb & Sons, L.L.C. | $230.07 | 2019-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $220.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.06 | 2023-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $211.56 | 2019-2025 | Repatha, Repatha |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $168.04 | 2025 | |
| Merck Sharp & Dohme LLC | $140.80 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $130.94 | 2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $117.68 | 2022-2024 | |
| Philips North America LLC | $111.67 | 2019-2023 | |
| Amarin Pharma, INC. | $99.28 | 2019-2022 | |
| Irhythm Technologies, INC. | $78.75 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Teleflex LLC | $75.20 | 2022-2025 | Guideliner |
| Cardiva Medical, INC. | $69.82 | 2019-2024 | Cardiva Vascade 6/7f Vcs |
| Alnylam Pharmaceuticals INC. | $61.67 | 2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.91 | 2019-2024 | Lifevest |
| Cordis US Corp. | $52.49 | 2021-2022 | |
| Lilly USA, LLC | $50.68 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $50.48 | 2024 | Arcalyst |
| Acist Medical Systems, INC. | $46.32 | 2022-2023 | |
| Astellas Pharma US INC | $36.06 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.81 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $27.47 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.92 | 2025 | Injectafer |
| Cvrx, INC. | $23.80 | 2025 | Barostim Neo System |
| Penumbra, INC. | $22.39 | 2025 | Indigo System |
| Elutia, INC. | $21.16 | 2022-2023 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Esperion Therapeutics, INC. | $18.48 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $17.92 | 2025 | Tryvio |
| Atricure, INC. | $17.73 | 2024 | |
| Becton, Dickinson and Company | $16.96 | 2024 | Rotarexs 6 F X 135 Cm |
| W. L. Gore & Associates, INC. | $16.35 | 2022 | |
| Surmodics, INC. | $15.56 | 2023 | Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System |
| Bard Peripheral Vascular, INC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Nukta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.